Protocadherin alpha-6 (PCDHA6)

Protocadherin alpha-6 is a neural cell adhesion protein encoded by the PCDHA6 gene and is a member of the protocadherin alpha gene cluster on human chromosome 5[1][2]. This gene cluster consists of multiple cadherin superfamily genes with an organization similar to immune receptor loci[1][2]. Protocadherin alpha-6 is an integral plasma membrane protein that contains six cadherin ectodomains in its extracellular region and a conserved cytoplasmic domain. It is primarily expressed in the central nervous system and plays a critical role in the establishment and maintenance of specific cell-cell connections in the brain, being particularly important for neural circuit development, synaptic specificity, and neuronal diversity[1][2][4]. Alternative splicing generates diverse isoforms, but the full-length nature of these variants is not fully determined[1][2]. Protocadherin alpha-6, like other clustered protocadherins, mediates cell-cell adhesion via both cis (same cell) and trans (cell to cell) interactions involving its extracellular (EC) domains, especially EC1–6, and these interactions are highly specific and important for neuronal self-recognition and non-self discrimination[4][3]. Mutations or altered expression of PCDHA6 have been implicated in neurological disorders such as autism spectrum disorder and potentially in prostate cancer, though the mechanistic links remain under investigation[2]. There are currently no approved drugs targeting protocadherin alpha-6, and it is not considered a therapeutic receptor, enzyme, or transporter per current knowledge. Note: Protocadherin alpha-6 is not generally classified as a druggable therapeutic target (such as a receptor or enzyme), but rather as a cell adhesion molecule critical for neurodevelopment, and its dysfunction is associated with disease risk rather than therapeutic targeting[1][2][4].

Other names

PCDHA6Protocadherin alpha 6